These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 24535009)

  • 1. Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study.
    Padwal R; Lin M; Etminan M; Eurich DT
    Hypertension; 2014 May; 63(5):977-83. PubMed ID: 24535009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors.
    Walker AM; Liang C; Clifford CR; Parker C; Feldman A
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):348-56. PubMed ID: 24375940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers.
    Graham DJ; Zhou EH; McKean S; Levenson M; Calia K; Gelperin K; Ding X; MaCurdy TE; Worrall C; Kelman JA
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):331-9. PubMed ID: 24277678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.
    Iseki K; Arima H; Kohagura K; Komiya I; Ueda S; Tokuyama K; Shiohira Y; Uehara H; Toma S;
    Nephrol Dial Transplant; 2013 Jun; 28(6):1579-89. PubMed ID: 23355629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of acute myocardial infarction, stroke, or death in patients initiating olmesartan or other angiotensin receptor blockers - a cohort study using the Clinical Practice Research Datalink.
    Zhou EH; Gelperin K; Levenson MS; Rose M; Hsueh YH; Graham DJ
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):340-7. PubMed ID: 24285502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of olmesartan and enteropathy outcomes: a multi-database study.
    Dong YH; Jin Y; Tsacogianis TN; He M; Hsieh PH; Gagne JJ
    Aliment Pharmacol Ther; 2018 Mar; 47(6):792-800. PubMed ID: 29359522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
    Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
    Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
    Haller H; Ito S; Izzo JL; Januszewicz A; Katayama S; Menne J; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G;
    N Engl J Med; 2011 Mar; 364(10):907-17. PubMed ID: 21388309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study.
    You SC; Park H; Yoon D; Park S; Joung B; Park RW
    Korean J Intern Med; 2019 Jan; 34(1):90-98. PubMed ID: 29172402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients.
    Swindle JP; Buzinec P; Iorga SR; Ramaswamy K; Panjabi S
    Curr Med Res Opin; 2011 Sep; 27(9):1719-31. PubMed ID: 21767101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial--rationale and design.
    Sakata Y; Nochioka K; Miura M; Takada T; Tadaki S; Miyata S; Shiba N; Shimokawa H
    J Cardiol; 2013 Jul; 62(1):31-6. PubMed ID: 23769179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study.
    Basson M; Mezzarobba M; Weill A; Ricordeau P; Allemand H; Alla F; Carbonnel F
    Gut; 2016 Oct; 65(10):1664-9. PubMed ID: 26250345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sprue-like histology in patients with abdominal pain taking olmesartan compared with other angiotensin receptor blockers.
    Lagana SM; Braunstein ED; Arguelles-Grande C; Bhagat G; Green PH; Lebwohl B
    J Clin Pathol; 2015 Jan; 68(1):29-32. PubMed ID: 25342757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes.
    Padwal R; Lin M; Eurich DT
    J Clin Hypertens (Greenwich); 2016 Mar; 18(3):200-6. PubMed ID: 26289255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
    Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
    Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sprue-like enteropathy linked to olmesartan.
    Campos Ruiz A; Urtasun Arlegui L; Marra-López Valenciano C
    Rev Esp Enferm Dig; 2016 May; 108(5):292-3. PubMed ID: 26925975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
    Shih CJ; Chu H; Ou SM; Chen YT
    Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.